Meeting: Advisory Board on Radiation and Worker Health (ABRWH), Subcommittee for Dose Reconstruction Reviews (SDRR), National Institute for Occupational Safety and Health (NIOSH), 43548-43549 [2021-16954]

Download as PDF lotter on DSK11XQN23PROD with NOTICES1 43548 Federal Register / Vol. 86, No. 150 / Monday, August 9, 2021 / Notices Broadcom from retaliating against a customer that refuses a prohibited majority share requirement or that purchases products from a competitor of Broadcom. Paragraph I of the proposed order defines the key terms used in the order. Paragraph II.A. of the proposed order prohibits Broadcom from imposing a majority share requirement on a customer’s purchases of any Monopolized Product. This provision is designed to end Broadcom’s exclusive dealing practices in the markets for Monopolized Products and to enable the emergence of effective competition in those markets. The prohibition applies to sales of Monopolized Products to OEMs and to U.S. service providers. The proposed order specifically includes prohibitions on Broadcom (1) conditioning the sale of a Monopolized Product on a majority share requirement for that product, (2) conditioning price terms, or non-price terms such as delivery or support terms, for a Monopolized Product on a majority share requirement for that product, (3) conditioning other payments on a majority share requirement for a Monopolized Product, or (4) providing certain types of retroactive rebates for a Monopolized Product in exchange for a majority share requirement. The prohibitions in Paragraph II.A. are qualified by a number of provisos designed to assure that the order does not bar Broadcom from competing on the merits. The first proviso clarifies that the order does not prohibit Broadcom from fulfilling orders from a customer that, over time, chooses to purchase more than 50% of its requirements from Broadcom, provided that such purchases are not pursuant to a majority share requirement prohibited by the order. The second proviso clarifies that a customer’s mere designation of Broadcom as an ‘‘authorized’’ or ‘‘preferred’’ provider does not alone establish a violation of the order. The third proviso clarifies that the order does not prohibit nonretroactive volume discounts. The fourth proviso allows Broadcom, in narrow circumstances, to enter into a majority share requirement in connection with a particular request for proposal (RFP). The proviso provides that Broadcom may agree to a singlesource term in connection with an RFP covering a single device model (or a single device model and certain limited derivatives thereof) if the customer structures the RFP in this way. (In contrast, if a customer chooses to structure an RFP to split component supply for a particular device among multiple suppliers, Broadcom may not VerDate Sep<11>2014 17:26 Aug 06, 2021 Jkt 253001 thwart this by insisting on exclusivity.) The fifth proviso enables Broadcom, in specified conditions, to agree to exclusivity terms with a customer to incent Broadcom to continue producing a product beyond its ordinary-course end of life. Paragraph II.B of the proposed order prohibits Broadcom from using its monopoly power in a Monopolized Product to impose majority share requirements for other Monopolized Products or Related Products. Paragraph II.C of the order prohibits Broadcom from retaliating against a customer for working with a Broadcom rival or for refusing to commit to or maintain a prohibited majority share requirement. Prohibited retaliation includes actual or threatened interference with the sale or delivery of Monopolized Products; withdrawal or modification of, or refusal to extend, relatively favorable price or non-price terms; or refusal to deal with the customer on terms generally available to other similarly situated customers. The proposed order contains standard provisions designed to ensure compliance. Paragraph III requires Broadcom to maintain an antitrust compliance program and to provide notice to customers of the prohibitions contained in the order. Paragraphs IV through VI contain provisions regarding compliance reports, notice of changes in respondent, and access to documents and personnel. The proposed Order’s prohibitions apply to agreements with Service Providers that serve end users in the United States and to agreements with OEMs worldwide, with the exception of agreements for the sale of products intended for use in devices for end users in China. These products are excluded from the prohibitions on majority share requirements in light of distinct competitive conditions applicable to them. The term of the proposed order is ten years. By direction of the Commission. Joel Christie, Acting Secretary. [FR Doc. 2021–16655 Filed 8–6–21; 8:45 am] BILLING CODE 6750–01–P PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Meeting: Advisory Board on Radiation and Worker Health (ABRWH), Subcommittee for Dose Reconstruction Reviews (SDRR), National Institute for Occupational Safety and Health (NIOSH) Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of meeting. AGENCY: In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Subcommittee for Dose Reconstruction Reviews (SDRR) of the Advisory Board on Radiation and Worker Health (ABRWH or the Advisory Board). This meeting is open to the public, but without a public comment period. The public is welcome to submit written comments in advance of the meeting, to the contact person below. Written comments received in advance of the meeting will be included in the official record of the meeting. The public is also welcomed to listen to the meeting by joining the audio conference (information below). The audio conference line has 150 ports for callers. DATES: The meeting will be held on September 29, 2021, from 10:30 a.m. to 4:00 p.m., EDT. Written comments must be received on or before September 22, 2021. ADDRESSES: You may submit comments by mail to: Sherri Diana, National Institute for Occupational Safety and Health, 1090 Tusculum Avenue, MS C–34, Cincinnati, Ohio 45226. Meeting Information: Audio Conference Call via FTS Conferencing. The USA toll-free dial-in number is 1–866–659–0537; the pass code is 9933701. SUMMARY: FOR FURTHER INFORMATION CONTACT: Rashaun Roberts, Ph.D., Designated Federal Officer, NIOSH, CDC, 1090 Tusculum Avenue, Mailstop C–24, Cincinnati, Ohio 45226, Telephone: (513) 533–6800; Toll Free 1(800)CDC– INFO; Email: ocas@cdc.gov. SUPPLEMENTARY INFORMATION: Background: The Advisory Board was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key E:\FR\FM\09AUN1.SGM 09AUN1 lotter on DSK11XQN23PROD with NOTICES1 Federal Register / Vol. 86, No. 150 / Monday, August 9, 2021 / Notices functions of the Advisory Board include providing advice on the development of probability of causation guidelines that have been promulgated by the Department of Health and Human Services (HHS) as a final rule; advice on methods of dose reconstruction, which have also been promulgated by HHS as a final rule; advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program; and advice on petitions to add classes of workers to the Special Exposure Cohort (SEC). In December 2000, the President delegated responsibility for funding, staffing, and operating the Advisory Board to HHS, which subsequently delegated this authority to CDC. NIOSH implements this responsibility for CDC. The Advisory Board’s charter was issued on August 3, 2001, renewed at appropriate intervals, and rechartered under Executive Order 13889 on March 22, 2020, and will terminate on March 22, 2022. Purpose: The Advisory Board is charged with (a) providing advice to the Secretary, HHS, on the development of guidelines under Executive Order 13179; (b) providing advice to the Secretary, HHS, on the scientific validity and quality of dose reconstruction efforts performed for this program; and (c) upon request by the Secretary, HHS, advise the Secretary on whether there is a class of employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is reasonable likelihood that such radiation doses may have endangered the health of members of this class. SDRR was established to aid the Advisory Board in carrying out its duty to advise the Secretary, HHS, on dose reconstruction. Matters To Be Considered: The agenda will include discussions on the following dose reconstruction program quality management and assurance activities: Dose reconstruction cases under review from Set 29, possibly including cases involving: Albuquerque Operations Office, Area IV of the Santa Susana Field Laboratory, Argonne National Laboratory-East, Argonne National Laboratory-West, Battelle Laboratories-King Avenue, Clarksville Modification Center, Feed Materials Production Center (FMPC), Fermi National Accelerator Laboratory, General Atomics, Hanford, Idaho National Laboratory, Lawrence Berkeley National Laboratory, Lawrence Livermore National Laboratory, Los Alamos National Laboratory, Mound VerDate Sep<11>2014 17:26 Aug 06, 2021 Jkt 253001 Plant, Nevada Test Site, Oak Ridge Gaseous Diffusion Plant (K–25), Oak Ridge Institute for Science and Education, Oak Ridge National Laboratory (X–10), Pacific Northwest National Laboratory, Paducah Gaseous Diffusion Plant, Pantex Plant, Portsmouth Gaseous Diffusion Plant, Rocky Flats Plant, Savannah River Site, and/or Y–12 Plant. If time permits, there may also be discussion on professional judgement in response to the April 12, 2021 SDRR report to the Advisory Board. Agenda items are subject to change as priorities dictate. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2021–16954 Filed 8–6–21; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Community Living Agency Information Collection Activities; Proposed Collection; Public Comment Request; Centers for Independent Living Program Performance Report (0985–0061) Administration for Community Living, Health and Human Services (HHS). AGENCY: ACTION: Notice. The Administration for Community Living (ACL) is announcing an opportunity for the public to comment on the proposed collection of information listed above. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish a notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This Proposed Extension without Revision of a Currently Approved Collection (ICR Ext) solicits comments on the information collection requirements relating to the Centers for SUMMARY: PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 43549 Independent Living under the Rehabilitation Act of 1973. DATES: Comments on the collection of information must be submitted electronically by 11:59 p.m. (EST) or postmarked by October 8, 2021. ADDRESSES: Submit electronic comments on the collection of information to: Peter Nye at OILPPRAComments@acl.hhs.gov. Submit written comments on the collection of information to Administration for Community Living, Washington, DC 20201, Attention: Peter Nye. FOR FURTHER INFORMATION CONTACT: Peter Nye, Administration for Community Living, Washington, DC 20024, (202) 795–7606 or OILPPRAComments@acl.hhs.gov. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ‘‘Collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, ACL is publishing a notice of the proposed collection of information set forth in this document. With respect to the following collection of information, ACL invites comments on our burden estimates or any other aspect of this collection of information, including: (1) Whether the proposed collection of information is necessary for the proper performance of ACL’s functions, including whether the information will have practical utility; (2) the accuracy of ACL’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used to determine burden estimates; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques when appropriate, and other forms of information technology. E:\FR\FM\09AUN1.SGM 09AUN1

Agencies

[Federal Register Volume 86, Number 150 (Monday, August 9, 2021)]
[Notices]
[Pages 43548-43549]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-16954]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Meeting: Advisory Board on Radiation and Worker Health (ABRWH), 
Subcommittee for Dose Reconstruction Reviews (SDRR), National Institute 
for Occupational Safety and Health (NIOSH)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC 
announces the following meeting for the Subcommittee for Dose 
Reconstruction Reviews (SDRR) of the Advisory Board on Radiation and 
Worker Health (ABRWH or the Advisory Board). This meeting is open to 
the public, but without a public comment period. The public is welcome 
to submit written comments in advance of the meeting, to the contact 
person below. Written comments received in advance of the meeting will 
be included in the official record of the meeting. The public is also 
welcomed to listen to the meeting by joining the audio conference 
(information below). The audio conference line has 150 ports for 
callers.

DATES: The meeting will be held on September 29, 2021, from 10:30 a.m. 
to 4:00 p.m., EDT. Written comments must be received on or before 
September 22, 2021.

ADDRESSES: You may submit comments by mail to: Sherri Diana, National 
Institute for Occupational Safety and Health, 1090 Tusculum Avenue, MS 
C-34, Cincinnati, Ohio 45226.
    Meeting Information: Audio Conference Call via FTS Conferencing. 
The USA toll-free dial-in number is 1-866-659-0537; the pass code is 
9933701.

FOR FURTHER INFORMATION CONTACT: Rashaun Roberts, Ph.D., Designated 
Federal Officer, NIOSH, CDC, 1090 Tusculum Avenue, Mailstop C-24, 
Cincinnati, Ohio 45226, Telephone: (513) 533-6800; Toll Free 1(800)CDC-
INFO; Email: [email protected].

SUPPLEMENTARY INFORMATION: 
    Background: The Advisory Board was established under the Energy 
Employees Occupational Illness Compensation Program Act of 2000 to 
advise the President on a variety of policy and technical functions 
required to implement and effectively manage the new compensation 
program. Key

[[Page 43549]]

functions of the Advisory Board include providing advice on the 
development of probability of causation guidelines that have been 
promulgated by the Department of Health and Human Services (HHS) as a 
final rule; advice on methods of dose reconstruction, which have also 
been promulgated by HHS as a final rule; advice on the scientific 
validity and quality of dose estimation and reconstruction efforts 
being performed for purposes of the compensation program; and advice on 
petitions to add classes of workers to the Special Exposure Cohort 
(SEC). In December 2000, the President delegated responsibility for 
funding, staffing, and operating the Advisory Board to HHS, which 
subsequently delegated this authority to CDC. NIOSH implements this 
responsibility for CDC.
    The Advisory Board's charter was issued on August 3, 2001, renewed 
at appropriate intervals, and rechartered under Executive Order 13889 
on March 22, 2020, and will terminate on March 22, 2022.
    Purpose: The Advisory Board is charged with (a) providing advice to 
the Secretary, HHS, on the development of guidelines under Executive 
Order 13179; (b) providing advice to the Secretary, HHS, on the 
scientific validity and quality of dose reconstruction efforts 
performed for this program; and (c) upon request by the Secretary, HHS, 
advise the Secretary on whether there is a class of employees at any 
Department of Energy facility who were exposed to radiation but for 
whom it is not feasible to estimate their radiation dose, and on 
whether there is reasonable likelihood that such radiation doses may 
have endangered the health of members of this class. SDRR was 
established to aid the Advisory Board in carrying out its duty to 
advise the Secretary, HHS, on dose reconstruction.
    Matters To Be Considered: The agenda will include discussions on 
the following dose reconstruction program quality management and 
assurance activities: Dose reconstruction cases under review from Set 
29, possibly including cases involving: Albuquerque Operations Office, 
Area IV of the Santa Susana Field Laboratory, Argonne National 
Laboratory-East, Argonne National Laboratory-West, Battelle 
Laboratories-King Avenue, Clarksville Modification Center, Feed 
Materials Production Center (FMPC), Fermi National Accelerator 
Laboratory, General Atomics, Hanford, Idaho National Laboratory, 
Lawrence Berkeley National Laboratory, Lawrence Livermore National 
Laboratory, Los Alamos National Laboratory, Mound Plant, Nevada Test 
Site, Oak Ridge Gaseous Diffusion Plant (K-25), Oak Ridge Institute for 
Science and Education, Oak Ridge National Laboratory (X-10), Pacific 
Northwest National Laboratory, Paducah Gaseous Diffusion Plant, Pantex 
Plant, Portsmouth Gaseous Diffusion Plant, Rocky Flats Plant, Savannah 
River Site, and/or Y-12 Plant. If time permits, there may also be 
discussion on professional judgement in response to the April 12, 2021 
SDRR report to the Advisory Board. Agenda items are subject to change 
as priorities dictate.
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-16954 Filed 8-6-21; 8:45 am]
BILLING CODE 4163-18-P